Prazosin is an alpha 1 adrenoceptor antagonist, and it is used as an antihypertensive agent. The effects of prazosin on the activity of hepatic triacylglycerole lipase (HTGL) are not fully understood. In this study, we demonstrated that prazosin stimulates the release of HTGL activity from primary cultures of rat hepatocytes in a time-and dose-dependent manner. U-73122, a phopholipase C (PLC) inhibitor, suppresses prazosin's stimulation of the release of HTGL activity. Moreover, prazosin stimulated the increase of PLC activity in the hepatocytes in a time-and dose-dependent manner. In addition, the prazosinstimulated release of HTGL activity was reduced by Quin2/AM (an intracellular Ca 2+ -chelator), W-7 (a Calmodulin inhibitor), and KN-93 [an inhibitor of Ca 2+ /Calmodulin dependent protein kinase (CaMK)-II]. These results suggest that the prazosin-stimulated release of HTGL activity is partly due to the activation of CaMK-II that is associated with the elevation of PLC activity in the hepatocytes.
INTRODUCTION
Prazosin ([4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone), which is a well-known depressor, competes with alpha 1 adrenoceptor. 1, 2) Previous reports show that administration of prazosin, in vivo, causes increases * To whom correspondence should be addressed: Department of Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, 985 Higashimura, Fukuyama, Hiroshima 729-0292, Japan. Tel.: +81-84-936-2111 (Ext. 5221); Fax: +81-84-936-2024; E-mail: morita@fupharm.fukuyamau.ac.jp in lipoprotein lipase (LPL) activity and decreases in 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activity. [3] [4] [5] [6] Prazosin also affects clinical indicators of lipid metabolism; for example, it results in the rise of the cholesterol ratio [high density lipoprotein (HDL)/very low density lipoprotein (VLDL) + low density lipoprotein (LDL)]. [7] [8] [9] However, the various effects of prazosin on lipid metabolism are not understood in detail.
Hepatic lipase (hepatic triacylglycerole lipase; HTGL, EC 3.1.1.3) plays an important role in lipid metabolism. [10] [11] [12] It is synthesized primarily by hepatocytes and released on the luminal endothelial cell surface where it hydrolyzes the triacylglycerole in high and intermediate density lipoproteins. HTGL deficiency causes hyperlipemia and arteriosclerosis. 12) In addition, administration of doxazosin, another type of alpha 1 adrenoceptor antagonist, was shown to increase HTGL activity in the liver, 13) but the mechanism of this process is currently not known.
In this study, we examined the effects of prazosin on the release of HTGL activity from primary cultures of rat hepatocytes. 14, 15) Contamination by Kupffer cells of the hepatocyte preparation was confirmed to be less than 2% by peroxidase staining. 16) Cell viability was determined by trypan blue exclusion and ranged from 85 to 95%. The hepatocytes were cultured for 24 hr in monolayers in a plastic dish (1 × 10 5 cell/cm 2 ) in Williams' medium E (containing 10% fetal calf serum, 10 nM insulin, 10 nM dexamethasone, and 5 kIU/ml aprotinin) in a 5% CO 2 atmosphere. After removal of the medium by aspiration, monolayers of hepatocytes in the dish were further incubated for 0-105 min in Williams' medium E containing 2% bovine serum albumin with various concentration (0-200 µM) of alpha 1 adrenoceptor antagonists (prazosin, terazosin, doxazosin, and 5-methylurapidil). The hepatocytes were harvested and centrifuged at 50 × g for 5 min to remove cellular debris. The supernatant obtained served as the preparation for assaying the release of HTGL activity. Determination of HTGL Activity --HTGL activity was determined by a method using glycerol tri[1-14 C]-oleate (1.2 µM; 2.5 kBq/ml) as a substrate. 17, 18) The HTGL activity was expressed as pmol of free fatty acids (FFA) produced/min par 10 6 cells. Determination of Phospholipase C (PLC) Activity --PLC activity was determined by the method of Higashi et al. 19) Briefly, the hepatocytes incubated with prazosin 0-100 µM over 30-min period, were homogenized in 20 mM Hepes-K buffer (pH 7.0) containing 1 mM dithiothreitol, 0.25 M sucrose, 1 mM EDTA and 0.7% cholateNa by Physcotron (a microhomogenizer; NS-310E model, Niti-on Co., Tokyo, Japan), and were centrifuged at 105000 × g for 60 min at 4 • C. The supernatant contained the cytosolic and membrane fractions. The supernatant was used as the PLC enzyme preparation to hydrolyze phosphatidyl[2-3 H]-inositol 4,5-bisphosphate as a substrate. 20) The free inositolphosphates released were extracted and quantified. The PLC activity was expressed as fmol/min par 10 6 cells.
MATERIALS AND METHODS

Materials
Data Analysis --In each experiment, results are the mean ± S.E. of three or four observations from separate experiments using different hepatocyte preparations. Figure 1(a) shows the changes in the release of HTGL activity from the hepatocytes incubated for 60 min with different adrenoceptor antagonists: prazosin, terazosin, doxazosin, or 5-methylurapidil. Only prazosin stimulated the release of HTGL activity from hepatocytes into the medium. Next, the hepatocytes incubated (100 µM prazosin) over a 105-min period [ Fig. 1(b) ]. A time-dependent release of HTGL activity from the hepatocytes was observed. Moreover, the effect of prazosin on the release of HTGL activity increased in a dosedependent manner up to 100 µM. When prazosin stimulated the release of HTGL from the hepatocytes into the medium, the enzyme activity in the hepatocytes decreased (data not shown).
RESULTS
Whether the stimulatory release of HTGL activity by prazosin is involved in PLC activity was examined. The hepatocytes were incubated with prazosin in the presence of U-73122, an inhibitor of PLC. The prazosin-stimulated release of HTGL activity was markedly suppressed by U-73122 (Fig. 2) , but it was not suppressed by U- 73343, which was an inactive analog of U-73122 21) and used as a negative control.
This increase in PLC activity in the hepatocytes by prazosin was examined. When the hepatocytes were incubated with prazosin at a concentration of 100 µM for up to 30 min, the PLC activity in the preparation from the incubated hepatocytes as described in Materials and Methods was increased in a time-dependent manner over 10 min [ Fig. 3(a) ]. Next, the hepatocytes incubated with different concentrations of prazosin (0-100 µM) for 10 min, PLC activity increased in a dose-dependent manner [ Fig. 3(b) ].
In addition, we investigated the effects of various modulators on the release of HTGL activity by prazosin (Fig. 4) . The prazosin-stimulated release of HTGL activity was suppressed by Quin2/AM 22) (an intracellar Ca 2+ -chelator), W-7 23) (a Ca 2+ /calmodulin inhibitor), and KN-93 24) [an inhibitor of Ca 2+ /calmodulin-dependent protein kinase (CaMK)-II] (Fig. 4) .
DISCUSSION
Changes in in vivo lipid metabolism following administration of prazosin have been reported previously. [7] [8] [9] However, the contribution of HTGL to these changes in lipid metabolism was not shown. In this report, we demonstrate that prazosin stimulates the release of HTGL from rat hepatocytes [ Fig. 1(a) and 1(b) ]. In contrast, the stimulation of HTGL release was hardly evident with any other alpha 1 adrenoceptor blocker at the concentrations examined [ Fig. 1(a) ]. Then, the stimulatory effect of prazosin was preserved in the presence of alpha 1 adrenoceptor agonists (data not shown). In this study, it is possible that the action of prazosin was caused by the uptake of prazosin into the hepatocytes, not by the interactions between the alpha 1 adrenoceptor and prazosin. Our data also suggested that the prazosin-stimulated release of HTGL activity is due to an activation of PLC activity in the hepatocytes (Figs. 2 and 3) . It is well-known that an activation of PLC results in an increased intracellular Ca 2+ concentration. 20) In our experiments, the stimulatory release of HTGL activity by prazosin was suppressed by an intracellular Ca 2+ -chelator (Fig. 4) . According to the report, 25) the maturation and the secretion of HTGL is inhibited by adrenaline though changes in Ca 2+ homeostasis. 25) The intracellular Ca 2+ contents may be important for the stimulatory release of HTGL activity by prazosin, an alpha 1 adrenoceptor antagonist. The prazosin-stimulated release of HTGL activity is also suppressed by inhibitors of Ca 2+ /calmodulin inhibitor and CaMK-II (Fig. 4) . Activation of CaMK-II induced by heparin was also reported to cause the stimulatory release of HTGL activity. 26) However, prazosin-stimulated release of HTGL activity was not suppressed by protein kinase C inhibitors (data not shown).
In conclusion, our results show that prazosin stimulated the release of HTGL activity from cultured rat hepatocytes, and the stimulatory action by prazosin may be due to the pathway involving an increase in the cytosolic Ca 2+ concentration through an activation of PLC activity, following activation of CaMK-II activity.
